Leukemia, Myelomonocytic, Juvenile: all 234 studies

Page 2 of 3. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantCompletedNCT00309907Phase 2Results posted
• Oral Clofarabine Study in Patients With Myelodysplastic SyndromeCompletedNCT00299156Phase 2Results posted
• Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT00167219Phase 1/2Results posted
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT00119366Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• HCT With PTCy in Higher-risk MDSActive, not recruitingNCT06098313Phase 2
• Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnNCT06085638Phase 1/2
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2
• A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
• Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With HemoblastosisActive, not recruitingNCT05515029Phase 3
• A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1
• A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
• Pharmacokinetics, Tolerability and Safety of NEX-18aCompletedNCT05048498Phase 1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Classical Monocyte Kinetics in Chronic Myelomonocytic LeukemiaCompletedNCT04775121Not applicable
• A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
• IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
• A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)WithdrawnNCT04264806Phase 2
• SNS-301 Monotherapy in High Risk MDS and CMMLWithdrawnNCT04217720Phase 2
• Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory LeukaemiaCompletedNCT04082286Phase 1
• A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyStatus unknownNCT03873311Phase 4
• Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
• Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
• Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
• A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesCompletedNCT03746041Phase 1
• Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic LeukemiaStatus unknownNCT03687463
• Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid MalignanciesActive, not recruitingNCT03682029Not applicable
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• Ascorbic Acid Levels in MDS, AML, and CMML PatientsCompletedNCT03526666
• Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
• Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic SyndromesCompletedNCT03363399
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)Status unknownNCT03040401Phase 1/2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
• Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
• Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
• Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
• Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT02546284Phase 1
• Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT02447666Phase 2
• Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesStatus unknownNCT02338479
• Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseCompletedNCT02197676Phase 2
• Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedNCT02190695Phase 2
• Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoLTerminatedNCT02147873Phase 2
• Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
• Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CompletedNCT02085798
• CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
• Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
• Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
• Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
• Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
• Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
• Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
• A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
• Registry on Hypomethylating Agents in Myeloid NeoplasmsCompletedNCT01595295
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
• 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)CompletedNCT01404741Phase 2
• Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsCompletedNCT01398462Phase 1
• Lenalidomide in Patients With Chronic Myelomonocytic LeukemiaStatus unknownNCT01368757Phase 1/2
• Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Status unknownNCT01339988Phase 4
• Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic LeukemiaCompletedNCT01251627Phase 2
• Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
• Azacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01235117Phase 2
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
• Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
• Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) FailureStatus unknownNCT01133886Phase 2
• Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01098084Phase 2
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01048034Phase 2
• Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
• The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic LeukemiaTerminatedNCT01010256
• Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
• Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With CancerCompletedNCT00898079
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
• Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
• A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
• Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesCompletedNCT00697671Phase 1
• Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
• Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
• Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsCompletedNCT00640796Phase 1

← Leukemia, Myelomonocytic, Juvenile overview